Gold Standard Diagnostics (GSD) today announced it offers a new B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA Screen that can be used to improve workflow and conserve testing resources. This assay has demonstrated increased sensitivity for early Lyme Disease detection - up to 20% over existing available Lyme screening assays - while maintaining 98% specificity. True Lyme negative samples are eliminated prior to second-tier testing.
The OspC antigen used in this assay is highly specific for the detection of IgM antibodies, and when used in combination with the recombinant VlsE, produces a superior first-tier screen.
Optimized to be used with both second-tier Immunoblots and the new Modified Two-Tier Test (MTTT) algorithm), this increase in first-tier test specificity will reduce the number of second-tier tests required. This test can be automated on any open EIA processor, Time and costs are dramatically reduced in workflow.